The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

AOD-9604 Dosage Guide

AOD-9604 is a synthetic fragment of human growth hormone (hGH 176–191) studied for fat metabolism. It received FDA GRAS designation in 2014. Its Phase 2b obesity trial (METAOD) did not meet its primary weight-loss endpoint, and results were not published in a peer-reviewed journal. Human fat-loss efficacy is not established.

Standard Research Dosage

250–500 mcg per day, administered subcutaneously. These are doses used in research — not protocols validated for human fat loss. Cycle length: 8–12 weeks.

Mechanism of Action

AOD-9604 mimics the lipolytic domain of hGH (amino acids 176–191) without binding to the IGF-1-stimulating domain. It activates beta-3 adrenergic receptors in adipose tissue, stimulating fat breakdown without the insulin resistance associated with full hGH.

Clinical Development History

AOD-9604's Phase 2b obesity trial (METAOD) did not meet its primary weight-loss endpoint, and the results were not published in a peer-reviewed journal. Phase 3 trials were not conducted. Human fat-loss efficacy is not established.